Epigenetics Diagnostic Market Size, Share, Sector / Industry Report & Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Epigenetics Diagnostic Market


The global Epigenetics Diagnostic market size is projected to reach US$ 21.82 billion by 2026, from US$ 7.76 billion in 2020, at a CAGR of 18.8% during 2021-2026. Increasing prevalence of cancer and other chronic diseases and growing geriatric population are some of the key factors expected to drive the market.

Presence of organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) is expected to fuel the market growth. These organizations promote funding and support R&D and product development exercises pertaining to the field of epigenetics. The NIH funds epigenetics research through Common fund epigenomics program, which actively supports new epigenetic research worldwide.

Growing need to understand the epigenetic modifications at the molecular level and development of therapeutic solutions is anticipated to motivate these organizations to fund research and development programs. In addition, endeavors such as the Epidemiology and Genomics Research Program (EGRP) in the NCIs Division of Cancer grants research initiatives owing to novel epigenetic research serves as a driving force of the market.

According to the NIH, the estimated number of cancer deaths in U.S. is 171.2 per 100,000 men and women per year. Incidence rate, mortality and survival statistics, information on cancer symptoms, risk factors, early detection, and early treatment are the key factors for its high prevalence. The International Cancer Genome Consortium (ICGC) is focusing on obtaining the genomic description, epigenomic changes, and transcriptomic changes in different types of tumors.

The Encyclopedia of DNA Elements (ENCODE) project was launched by the U.S. National Human Genome Research Institute with an objective to identify all the human genome sequence functional elements. The International Human Epigenome Consortium (IHEC), built by the NIH is also involved in the development of epigenomic data generation and analysis, which can be made useful for epigenomic researchers. Majorly, epigenetics research is focusing on the identification of treatment options for various types of tumors.

Market Segmentation, Outlook & Viewpoint: Global Epigenetics Diagnostic Market

Product Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

Reagents

Kits

  
ChIP Sequencing Kit
  
Whole Genomic Amplification Kit
  
Bisulfite Conversion Kit
  
RNA Sequencing Kit
  
Others

Instruments

Enzymes

Services

Technology Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

DNA Methylation

  
Reagents
  
Kits
  
Instruments
  
Enzymes
  
Services

Histone Methylation

  
Reagents
  
Kits
  
Instruments
  
Enzymes
  
Services

Histone Acetylation

  
Reagents
  
Kits
  
Instruments
  
Enzymes
  
Services

Large non-coding RNA

  
Reagents
  
Kits
  
Instruments
  
Enzymes
  
Services

MicroRNA Modification

  
Reagents
  
Kits
  
Instruments
  
Enzymes
Services

Chromatin structures

  
Reagents
  
Kits
  
Instruments
  
Enzymes
  
Services

Application Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

Oncology

  
Solid Tumors
Liquid Tumors

Non-oncology

  
Inflammatory Diseases
  
Metabolic Diseases
  
Infectious Diseases
  
Cardiovascular Diseases
  
Others

Key Players, Recent Developments & Regional Insights: Global Epigenetics Diagnostic Market

The reagents segment dominated the epigenetics diagnostic market in 2018. Histone and DNA modifiers are the major types of reagents used for epigenetics. Epigenetic reagents are segmented into antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, and buffers. PyroMark Q24 is one of the advanced reagents featuring advanced pyrosequencing chemistry to provide even better real-time sequence-based detection and quantification than before.

Existence of a number of technology platforms facilitates analysis at the gene, protein, or cellular levels, which leads to innovation in epigenetic reagents. The polymerase chain reaction (PCR) established a platform for genomic. Gene regulation is impacted by epigenetic factors such as chromatin structure, DNA methylation, and non-coding RNAs. The life sciences and analytical tools market is mostly driven by the widespread use of reagents.

The kits product segment is likely to emerge as the fastest-growing segment over the forecast period. The ready-to-use kits are manufactured by many biotechnology companies for detection of epigenetic modifications. Kits available in the market range from kits for nucleic acid purification, analysis of DNA methylation status, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are used for the diagnosis of disorders due to epigenetic modifications in early stages and during treatment to check the efficacy of therapeutics. They work on the basis of immunoprecipitation by involvement of modification-specific monoclonal antibodies.

Technology Insights

DNA methylation emerged as the largest segment in 2018. It is the covalent addition of a methyl group in the cytosine ring, which leads to inhibition of transcription. Sensitive bisulphite modification, followed by PCR, is performed called as Methylation Sensitive PCR (MSP).

Real time PCR for methylation detection, methyl light and quantitative analysis of methylated alleles are the variations of MSP. Currently, quantitative methods such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR, followed by MALDI-TOF MS are also useful for DNA methylation. Advancement of technologies is increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale.

Histone Acetylation is expected to witness the fastest growth over the forecast period owing to their enhanced efficacy, which could be attributed to introduction of novel mechanisms. Histone acetylation is the enzymatic incorporation of an acetyl group to lysine residues. Histone acetylation is involved in the control of cellular processes such as gene silencing, chromatin transcription and dynamics, progression of cell cycle, differentiation, apoptosis, DNA replication, neuronal repression, nuclear import, and DNA repair. The enzymes involved in histone acetylation are Histone Acetyl Transferases (HATs) and the enzymes involved in deacetylation are histone deacetylases (HDACs).

Application Insights

Oncology dominated the overall market in 2018 accounting for 69.6% share of the overall revenue. Increasing prevalence of cancer worldwide, along with increasing deaths due to cancer, is expected to be a high-impact rendering driver in the market. Moreover, this segment is expected to gain a major revenue share over the forecast period owing to introduction of new products and potential future commercialization of products currently in the pipeline.

Hypermethylation and epigenetic silencing are known as epimutations, occurring due to epigenetic changes. Epimutations have been known to be involved in the etiology of cancers. Extensive R&D is carried out for detecting epimutations, specifically related to silencing of tumor suppressor genes and activation of oncogenes. Unlike regular mutations, epimutations are reversible in nature.

Non-oncology is estimated to be the fastest-growing segment owing to rigorous R&D initiatives undertaken by private institutions and biopharmaceutical companies for identification of epigenetic markers related to these disorders.Epigenetic modifications have been proved to be the base of many non-oncology disorders, such as metabolic disorders, neurodegenerative disorders, and infectious diseases. Extensive research is undertaken by private institutions and biopharmaceutical companies for detection of biomarkers for drug development.

Regional Insights

North America emerged as the dominant regional market in 2018. Prominent drivers in the market are presence of advanced technological facilities, successful initiatives, constantly increasing geriatric population, improved healthcare facilities, government funding for ongoing research activities on epigenetics, diligent research, and accurate diagnostic procedures.

In addition, the Common Fund supported programs in U.S. are expected to boost the epigenetic research activities covering a diversified range of diseases including oncology and non-oncology diseases, such as cardiovascular, metabolic, and inflammatory.

Asia Pacific is estimated to witness the fastest growth over the forecast period owing to rising disposable income, high unmet clinical needs of patients, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China.Asia Pacific is in limelight due to increasing cases of various types of cancers.

Increasing cases of oncology as well as chronic diseases due to growth in geriatric population are expected to further enhance market growth. R&D initiatives related to analysis of epigenetic base in various diseases are increasing in this region. EpiGen Research Consortium based in U.K. has extended its research facility in Singapore for research on chronic diseases, such as diabetes and obesity.

Epigenetics Diagnostic Market Share Insights

Key players in this industry are Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; and Novartis AG. Major players are focusing on expanding their businesses in developing regions to increase their market share.
In addition, they are adopting strategies such as mergers and acquisitions and development of new products. For instance, in March 2015, Illumina, Inc. collaborated with Merck Serono to develop a universal next-sequencing-based oncology diagnostic.

Key Insights Covered: Global Epigenetics Diagnostic Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Epigenetics Diagnostic industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Epigenetics Diagnostic industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Epigenetics Diagnostic industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Epigenetics Diagnostic industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Epigenetics Diagnostic industry.

Research Methodology: Global Epigenetics Diagnostic Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other